(Q34133623)

31 July 2017

1 reference

title

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab (English)

1 reference

31 July 2017

1 reference

1 reference

1 reference

Sacchi S

1

1 reference

31 July 2017

Federico M

2

1 reference

31 July 2017

Federico M

3

1 reference

31 July 2017

Dastoli G

4

1 reference

31 July 2017

Fiorani C

5

1 reference

31 July 2017

Vinci G

6

1 reference

31 July 2017

Clò V

7

1 reference

31 July 2017

Casolari B

8

1 reference

31 July 2017

publication date

1 January 2001

1 reference

Critical Reviews in Oncology Hematology

31 July 2017

published in

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

13-25

1 reference

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Monoclonal antibody-based therapies for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Role of the Bp35 cell surface polypeptide in human B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900069-X

7 January 2021

10.1016/S1040-8428(00)00069-X

Identifiers

DOI

1 reference

31 July 2017

1 reference